AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26720026 — intervention group
Group type: EXPERIMENTAL
Intervention: 12F chest tube (n=54)
Number of subjects: 320
Study 26720026 — intervention group
Group type: COMPARATOR
Intervention: 24F chest tube (n=56)
Number of subjects: 320
Study 24821885 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1,400 mg)
Number of subjects: 278
Study 24821885 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 278
Study 24821885 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (375 mg/m2, 625 mg/m2, or 800 mg/m2)
Number of subjects: 278
Study 22975039 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal high-intensity focused ultrasound (HIFU)
Number of subjects: 34
Study 22975039 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 34
Study 22975039 — intervention group
Group type: COMPARATOR
Intervention: SVL group (splenic vein ligation)
Number of subjects: 34
Study 22975039 — intervention group
Group type: EXPERIMENTAL
Intervention: SVL + HIFU group
Number of subjects: 34
Study 19182179 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1.5-6.0 mg/day (regimen A)
Number of subjects: 257
Study 19182179 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 0.15-0.6 mg/day (regimen B)
Number of subjects: 257
Study 17518101 — intervention group
Group type: EXPERIMENTAL
Intervention: Accent on subject
Number of subjects: 0
Study 17518101 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch accents within a potential antecedent VP
Number of subjects: 0
Study 17518101 — intervention group
Group type: COMPARATOR
Intervention: Antecedents containing a focused constituent
Number of subjects: 0
Study 15615503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study 11450689 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 11
Study 9808278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic skin response (SSR) in ALS patients
Number of subjects: 31
Study 9808278 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar SSR in ALS patients
Number of subjects: 31
Study 9808278 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 31
Study 8541533 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146
Study 8541533 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146
Study 8541533 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146
Study 8541533 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 U rHuEpo daily subcutaneously for 8 weeks
Number of subjects: 146
Study 8541533 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 146
Study 2136809 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg toremifene
Number of subjects: 70
Study 2136809 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg toremifene
Number of subjects: 70
Study 2136809 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg toremifene
Number of subjects: 70
Study 2136809 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg toremifene
Number of subjects: 70
Study 2136809 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg toremifene
Number of subjects: 70
Study 2136809 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg toremifene
Number of subjects: 70
Study 678886 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a dietitian
Number of subjects: 49
Study 678886 — intervention group
Group type: COMPARATOR
Intervention: Diet sheet
Number of subjects: 49
Study 678886 — intervention group
Group type: COMPARATOR
Intervention: Doctor's advice to reduce weight
Number of subjects: 49
Study 31770513 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA CE high-dose (0.1% eye drops, 4 times daily)
Number of subjects: 142
Study 31770513 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA CE low-dose (0.1% eye drops, twice daily + vehicle twice daily)
Number of subjects: 142
Study 31770513 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 142
Study 31721907 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 31721907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 31721907 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 28294488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once daily
Number of subjects: 0
Study 28294488 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 0.5 mg once daily
Number of subjects: 0
Study 28294488 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 28294488 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 26363701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus standard care (medication and contact with the local clinical team)
Number of subjects: 50
Study 26363701 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 50
Study 26363701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 50
Study 24548978 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule formulation of lenvatinib (10 mg)
Number of subjects: 36
Study 24548978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with capsule formulation of lenvatinib (10 mg)
Number of subjects: 36
Study 24548978 — intervention group
Group type: COMPARATOR
Intervention: Tablet formulation of lenvatinib (10 mg)
Number of subjects: 36
Study 22989893 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 3
Study 22989893 — intervention group
Group type: COMPARATOR
Intervention: Surveillance per AACE/AAES guidelines
Number of subjects: 3
Study 22989893 — intervention group
Group type: COMPARATOR
Intervention: No follow-up (sign-off)
Number of subjects: 3
Study 19876883 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait re‐education programme and bed exercises (Group A)
Number of subjects: 60
Study 19876883 — intervention group
Group type: COMPARATOR
Intervention: Gait re‐education programme without bed exercises (Group B)
Number of subjects: 60
Study 17548662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 8369
Study 17548662 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8369
Study 15042464 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enhanced MRI using dynamically acquired T1 parameter maps
Number of subjects: 8
Study 15042464 — intervention group
Group type: COMPARATOR
Intervention: Standard pulmonary function test (PFT)
Number of subjects: 8
Study 11583482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg bid) with digoxin (1 mg)
Number of subjects: 12
Study 11583482 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 12
Study 11583482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (6 mg bid)
Number of subjects: 12
Study 9851574 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 163
Study 9851574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 7859889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean total urinary iodine excretion (UIT)
Number of subjects: 120
Study 7859889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean urinary iodine concentration (UIC)
Number of subjects: 120
Study 7859889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of UIT with serum nonhormonal iodine
Number of subjects: 120
Study 7859889 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of UIC with serum nonhormonal iodine
Number of subjects: 120
Study 7859889 — intervention group
Group type: COMPARATOR
Intervention: UIT in the 3rd decade compared to the 6th decade
Number of subjects: 120
Study 7859889 — intervention group
Group type: EXPERIMENTAL
Intervention: UIT increase with age up to the 6th decade
Number of subjects: 120
Study 7859889 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of UIT
Number of subjects: 120
Study 7859889 — intervention group
Group type: EXPERIMENTAL
Intervention: Rates of renal iodine clearance (UIC/SNI) in the 6th decade
Number of subjects: 120
Study 1701715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical tap to the fifth finger (targets)
Number of subjects: 0
Study 1701715 — intervention group
Group type: COMPARATOR
Intervention: Mechanical tap to the second finger (standards)
Number of subjects: 0
Study 1701715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical tap to the third or fourth finger (tactile novels)
Number of subjects: 0
Study 1701715 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric shock at the wrist (shock novels)
Number of subjects: 0
Study 1701715 — intervention group
Group type: EXPERIMENTAL
Intervention: P300 amplitude to shock and tactile novel stimuli
Number of subjects: 0
Study 216264 — intervention group
Group type: EXPERIMENTAL
Intervention: Proflavine
Number of subjects: 157
Study 216264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 30974479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy (CFT)
Number of subjects: 121
Study 30974479 — intervention group
Group type: COMPARATOR
Intervention: Manual Therapy and Exercise (MT-EX)
Number of subjects: 121
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning condition in individual competition (men)
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning condition in team competition (women)
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Losing condition in team competition (men)
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in women (naturally cycling) after winning
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in women (naturally cycling) after losing
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in men after losing
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in men after winning
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in male teams after losing
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nPower in individual competitions (women)
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nAffiliation in women competing as teams
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit motive nAffiliation in women competing individually
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression in men, losers, and teams
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression in women competing individually
Number of subjects: 326
Study 28750061 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression in women competing as teams and in men generally
Number of subjects: 326
Study 24952472 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized out-of-home activity intervention delivered by volunteers (once a week for 3 months)
Number of subjects: 121
Study 24280463 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 29
Study 24280463 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 29
Study 21446235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hood nebulization of 0.30 mg/kg salbutamol
Number of subjects: 26
Study 21446235 — intervention group
Group type: COMPARATOR
Intervention: Mask nebulization of 0.30 mg/kg salbutamol
Number of subjects: 26
Study 19371494 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 341
Study 16411994 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester ultrasound dating scan (scan group) between 8 and 12 weeks, measuring crown‐rump length.
Number of subjects: 463
Study 16411994 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound dating scan (no-scan group), gestation determined using last menstrual period (LMP).
Number of subjects: 463
Study 16786214 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 0.75 mg/Kg/day
Number of subjects: 67
Study 16786214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 67
Study 12768947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin
Number of subjects: 1707
Study 12768947 — intervention group
Group type: COMPARATOR
Intervention: 2-weekly intramuscular penicillin
Number of subjects: 1707
Study 12768947 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly intramuscular penicillin
Number of subjects: 1707
Study 10547167 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg twice daily) and clarithromycin (500 mg three times daily) for 14 days
Number of subjects: 100
Study 10547167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10547167 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent H. pylori infection
Number of subjects: 100
Study 10547167 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication of H. pylori
Number of subjects: 100
Study 8933774 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine 12 mg
Number of subjects: 287
Study 8933774 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 287
Study 8933774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 1831533 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of OK‐432
Number of subjects: 25
Study 1831533 — intervention group
Group type: COMPARATOR
Intervention: Intratumoral injection of physiological saline
Number of subjects: 25
Study 1831533 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 6137325 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide, 80 mg/day; Chlorthalidone, 100 mg/day
Number of subjects: 16
Study 6137325 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone, 100 mg/day
Number of subjects: 16
Study 6137325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid, 250 mg/day
Number of subjects: 16
Study 6137325 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopamide, 5 mg/day
Number of subjects: 16
Study 6137325 — intervention group
Group type: EXPERIMENTAL
Intervention: Muzolimine, 20 to 40 mg/day
Number of subjects: 16
Study 6137325 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide, 2.5 mg/day
Number of subjects: 16
Study 6137325 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone, 100 mg/day + beta-blocker (propranolol or atenolol)
Number of subjects: 16
Study 6137325 — intervention group
Group type: COMPARATOR
Intervention: Clopamide + beta-blocker (pindolol, 10 mg/day)
Number of subjects: 16
Study 31828602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical magnetic stimulation (Subgroup A-I and B-I)
Number of subjects: 40
Study 31828602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral magnetic stimulation (Subgroup A-II and B-II)
Number of subjects: 40
Study 31828602 — intervention group
Group type: COMPARATOR
Intervention: Control group (Subgroup A-II and B-II)
Number of subjects: 40
Study 31828602 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Quality of Life (I-QOL) questionnaire
Number of subjects: 40
Study 30261903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 0
Study 30261903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 75 mg
Number of subjects: 0
Study 30261903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (3 times daily from 3 days before planned delivery until actual delivery)
Number of subjects: 0
Study 28298777 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine buccal infiltration
Number of subjects: 90
Study 28298777 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine conventional anesthesia (control group)
Number of subjects: 90
Study 26187260 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV-HD
Number of subjects: 1000
Study 23054175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment (CBT) added to managed care
Number of subjects: 154
Study 23054175 — intervention group
Group type: COMPARATOR
Intervention: Managed care only
Number of subjects: 154
Study 21436594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 326
Study 21436594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 326
Study 21436594 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 326
Study 18641709 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IM training)
Number of subjects: 30
Study 18641709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (minimal inspiratory load)
Number of subjects: 30
Study 18641709 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 30
Study 16972832 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum plaster at Zusanli acupoints
Number of subjects: 108
Study 16972832 — intervention group
Group type: COMPARATOR
Intervention: Capsicum plaster on shoulders (Sham)
Number of subjects: 108
Study 16972832 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape at Zusanli acupoints and on shoulder (Control)
Number of subjects: 108
Study 12719164 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrical stimulation machine
Number of subjects: 34
Study 12719164 — intervention group
Group type: COMPARATOR
Intervention: Dummy machine (no current)
Number of subjects: 34
Study 11045873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC) pill
Number of subjects: 0
Study 9326125 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced pump system that controls both pressure and flow of fluid delivered
Number of subjects: 0
Study 9326125 — intervention group
Group type: COMPARATOR
Intervention: Air-driven diaphragm pump that only controls fluid pressure
Number of subjects: 0
Study 8454328 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR vaccine 30 micrograms
Number of subjects: 35
Study 8454328 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR vaccine 60 micrograms
Number of subjects: 35
Study 8454328 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR vaccine 120 micrograms
Number of subjects: 35
Study 8454328 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR vaccine 240 micrograms
Number of subjects: 35
Study 8454328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3535327 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 micrograms LT4 (group A)
Number of subjects: 54
Study 3535327 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms LT4 + 15 micrograms LT3 (group B)
Number of subjects: 54
Study 29747048 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone‐based exercise intervention
Number of subjects: 450
Study 29747048 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone‐based wellness/support intervention
Number of subjects: 450
Study 29747048 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 450
Study 27166295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir (DRV/r)
Number of subjects: 273
Study 27166295 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 273
Study 27166295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 273
Study 24857356 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMT)
Number of subjects: 200
Study 24857356 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (PG)
Number of subjects: 200
Study 22389244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 22389244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22389244 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 0
Study 22389244 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 19883909 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mm threaded screws
Number of subjects: 432
Study 19883909 — intervention group
Group type: COMPARATOR
Intervention: 32 mm threaded screws
Number of subjects: 432
Study 18940656 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate management protocol
Number of subjects: 34
Study 18940656 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 34
Study 16317122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol from 3 large eggs (EGG) daily
Number of subjects: 42
Study 16317122 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-free, fat-free egg substitute (SUB)
Number of subjects: 42
Study 14669411 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab (Synagis)
Number of subjects: 0
Study 14669411 — intervention group
Group type: COMPARATOR
Intervention: No protection
Number of subjects: 0
Study 10804324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) concentrations and apolipoprotein(a) molecular weights
Number of subjects: 148
Study 10804324 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo(a) phenotypes determined using 4‐15% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by immunoblotting
Number of subjects: 148
Study 10804324 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes population
Number of subjects: 148
Study 8893979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Type IIIR sealants
Number of subjects: 104
Study 8893979 — intervention group
Group type: COMPARATOR
Intervention: Fuji Type IXR sealants
Number of subjects: 104